Brusatol, an inhibitor of Nrf2, has been demonstrated to abrogate gemcitabine-induced Nrf2 activation, increase ROS accumulation, and potentiate gemcitabine-induced growth inhibition and cytotoxicity in pancreatic cancer cells (181). Here, NFE2L2 is linked to pancreatic neoplasm.